Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Biogen Inc Stock , BIIB

263.16 0.00 0.00%
Official Close 3/17/2023 NAS
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 03/17/2023 the closing price of the Biogen Inc share was $263.16 on NAS. Compared to the opening price on Friday 03/17/2023 on NAS of $264.79, this is a drop of 0.62%. Biogen Inc's market capitalization is $37.93 B by 144.49 M shares outstanding.
Is Biogen stock a Buy, Sell or Hold? Biogen stock has received a consensus rating of buy. The average rating score is Baa2 and is based on 65 buy ratings, 34 hold ratings, and 0 sell ratings.
What was the 52-week low for Biogen stock? The low in the last 52 weeks of Biogen stock was 187.22. According to the current price, Biogen is 140.56% away from the 52-week low.
What was the 52-week high for Biogen stock? The high in the last 52 weeks of Biogen stock was 311.79. According to the current price, Biogen is 84.40% away from the 52-week high.
What are analysts forecasts for Biogen stock? The 99 analysts offering price forecasts for Biogen have a median target of 308.05, with a high estimate of 500.00 and a low estimate of 195.00. The median estimate represents a 85.43 difference from the last price of 263.16.

Biogen Stock Snapshot

263.02
Bid
2,000.00
Bid Size
263.10
Ask
100.00
Ask Size
3/17/2023
Date
8:00 PM
Time
858,169.00
Volume
265.25
Prev. Close
264.79
Open
37.93 B
Market Cap
144.49 M
Number of Shares
260.74
Day Low
264.97
Day High
263.16
187.22
52 Week Low
311.79
52 Week High
263.16
0.00
Dividend
15.56
P/E Ratio
99.57
Free Float in %
15.53
EPS 2023
105.87
Book Value per Share
22.41
Cash Flow per Share

Biogen Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Biogen Analyst Data

Total Analysts: 99
Buy Ratings: 65 Neutral Ratings: 34 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 195.00 Median: 308.05 Highest: 500.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Biogen Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
02/16/23 Cowen and Company, LLC
Maintained Buy $315
02/16/23 UBS
Maintained Buy $340
02/16/23 Morgan Stanley
Maintained Buy $351
02/16/23 RBC Capital Markets
Maintained Buy $333
02/16/23 Oppenheimer & Co. Inc.
Maintained Buy $310
02/16/23 H.C. Wainwright & Co.
Maintained Buy $325
02/15/23 Needham & Company, LLC
Maintained Buy $325
01/24/23 Morgan Stanley
Maintained Buy $345
12/01/22 Atlantic Equities
Maintained Hold $295
11/30/22 Jefferies & Company Inc.
Maintained Buy $350
11/30/22 Wedbush Morgan Securities Inc.
Maintained Hold $247
11/30/22 Barclays Capital
Maintained Hold $313
11/14/22 Oppenheimer & Co. Inc.
Maintained Buy $315
11/11/22 Guggenheim
Maintained Hold $270
11/01/22 Mizuho
Maintained Buy $325
10/26/22 Morgan Stanley
Maintained Buy $325
10/26/22 Goldman Sachs
Upgraded to Buy $370
10/26/22 RBC Capital Markets
Maintained Buy $331
10/26/22 H.C. Wainwright & Co.
Maintained Buy $325
10/26/22 Atlantic Equities
Maintained Hold $220
10/26/22 SVB Leerink
Maintained Buy $310
10/24/22 Jefferies & Company Inc.
Maintained Buy $325
10/13/22 Morgan Stanley
Maintained Buy $321
10/13/22 Stifel, Nicolaus & Co., Inc.
Upgraded to Buy $299
10/07/22 Argus Research Company
Upgraded to Buy
10/07/22 Barclays Capital
Maintained Hold $275
10/06/22 UBS
Maintained Buy $309
09/30/22 J.P. Morgan
Maintained Hold $275
09/28/22 Wedbush Morgan Securities Inc.
Maintained Hold $217
09/28/22 Wells Fargo & Co
Maintained Buy $350
09/28/22 RBC Capital Markets
Maintained Buy $321
09/28/22 Piper Sandler
Maintained Hold $280
09/28/22 Baird Patrick & Co
Upgraded to Buy $340
09/28/22 BMO Capital Markets
Upgraded to Buy $360
09/28/22 Mizuho
Upgraded to Buy $270
09/12/22 Stifel, Nicolaus & Co., Inc.
Maintained Buy $223
07/21/22 Cowen and Company, LLC
Maintained Buy $270
07/21/22 Barclays Capital
Maintained Hold $200
07/21/22 Needham & Company, LLC
Maintained Buy $250
07/18/22 Oppenheimer & Co. Inc.
Maintained Buy $230
05/04/22 Morgan Stanley
Maintained Buy $285
05/04/22 Oppenheimer & Co. Inc.
Maintained Buy $225
05/04/22 RBC Capital Markets
Maintained Buy $251
05/04/22 Barclays Capital
Maintained Hold $210
04/21/22 SVB Leerink
Maintained Buy $270
04/18/22 Wells Fargo & Co
Upgraded to Buy $265
04/12/22 Morgan Stanley
Maintained Buy $283
04/12/22 Barclays Capital
Maintained Hold $219
04/08/22 Oppenheimer & Co. Inc.
Maintained Buy $240
04/08/22 Needham & Company, LLC
Maintained Buy $262

Biogen Estimates* in USD

  2023 2024 2025 2026 2027
Revenue 9,572 9,394 9,608 10,067 10,591
Dividend 0.00 0.00 0.00 0.00 0.00
Dividend Yield (in %) - - - - -
EPS 15.53 16.36 17.54 19.96 22.35
P/E Ratio 17.13 16.26 15.17 13.33 11.90
EBIT 2,731 2,848 3,040 3,410 3,763
EBITDA 3,311 3,321 3,491 3,987 4,185
Net Profit 2,245 2,337 2,494 2,834 3,130
Net Profit Adjusted 2,232 2,314 2,451 2,764 3,076
Pre-Tax Profit 2,632 2,769 2,980 3,371 3,747
Net Profit (Adjusted) 2,700 2,959 3,255 4,597 4,595
EPS (Non-GAAP) ex. SOE 16.18 17.37 19.03 21.04 22.51
EPS (GAAP) 14.86 15.12 16.27 17.79 21.51
Gross Income 7,462 7,679 8,176 8,729 9,096
Cash Flow from Investing -210 -363 -449 -251 -249
Cash Flow from Operations 2,997 3,216 3,308 3,665 3,856
Cash Flow from Financing -405 -953 -1,824 -1,145 -1,099
Cash Flow per Share 22.41 23.02 23.01 26.13 27.14
Free Cash Flow 2,589 2,803 2,777 2,893 3,067
Free Cash Flow per Share 22.90 22.20 21.20 24.10 25.10
Book Value per Share 105.87 117.94 131.73 176.50 202.20
Net Debt -1,268 -3,006 -4,256 -12,441 -16,082
Research & Development Exp. 2,215 2,149 2,136 2,120 2,180
Capital Expenditure 290 360 297 285 286
Selling, General & Admin. Exp. 2,276 2,272 2,278 2,319 2,404
Shareholder’s Equity 15,041 17,156 19,198 21,982 24,530
Total Assets 27,004 28,814 30,081 31,772 34,295
  Previous Quarter
ending 12/31/22 		Current Quarter
ending 03/31/23 		Next Quarter
ending 06/30/23 		Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts 24 23 23 26 26
Average Estimate 3.493 USD 3.389 USD 3.993 USD 15.529 USD 16.360 USD
Year Ago 3.390 USD 3.620 USD 5.250 USD 17.670 USD 15.529 USD
Publish Date 2/15/2023 4/26/2023 7/25/2023 - -
Revenue Estimates
No. of Analysts 23 23 22 28 28
Average Estimate 2,446 USD 2,357 USD 2,410 USD 9,572 USD 9,394 USD
Year Ago 2,734 USD 2,532 USD 2,589 USD 10,173 USD 9,572 USD
Publish Date 2/15/2023 4/26/2023 7/25/2023 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Biogen Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Singhal Priya 03/01/2023 144.00 3,410.39 268.75 Sell No
Singhal Priya 03/01/2023 543.00 3,257.39 268.75 Sell No
Singhal Priya 03/01/2023 297.00 3,554.39 n/a Buy No
Murphy Nicole 02/16/2023 233.00 5,099.29 278.38 Sell No
Gregory Ginger 02/16/2023 867.00 9,280.02 278.38 Sell No
ALEXANDER SUSAN H 02/16/2023 929.00 45,911.00 278.38 Sell No
Izzar Rachid 02/16/2023 371.00 5,117.00 278.38 Sell No
Singhal Priya 02/16/2023 151.00 3,800.39 278.38 Sell No
Kramer Robin 02/16/2023 238.00 3,331.75 278.38 Sell No
MCDONNELL MICHAEL R 02/16/2023 1,310.00 7,586.00 278.38 Sell No
Murphy Nicole 02/16/2023 480.00 5,579.29 n/a Buy No
Gregory Ginger 02/16/2023 1,792.00 11,072.02 n/a Buy No
ALEXANDER SUSAN H 02/16/2023 1,920.00 46,840.00 n/a Buy No
Izzar Rachid 02/16/2023 767.00 5,884.00 n/a Buy No
Singhal Priya 02/16/2023 460.00 3,951.39 n/a Buy No
Kramer Robin 02/16/2023 512.00 3,843.75 n/a Buy No
MCDONNELL MICHAEL R 02/16/2023 2,561.00 10,147.00 n/a Buy No
ALEXANDER SUSAN H 02/09/2023 2,737.00 44,920.00 286.30 Sell No
ALEXANDER SUSAN H 02/09/2023 701.00 47,657.00 286.30 Sell No
ALEXANDER SUSAN H 02/09/2023 764.00 46,910.00 286.30 Sell No
Murphy Nicole 02/09/2023 165.00 5,332.29 286.30 Sell No
Murphy Nicole 02/09/2023 537.00 5,497.29 286.30 Sell No
Murphy Nicole 02/09/2023 685.00 5,694.29 286.30 Sell No
Kramer Robin 02/09/2023 261.00 3,569.75 286.30 Sell No
Kramer Robin 02/09/2023 67.00 3,830.75 286.30 Sell No

Biogen Dividend Calendar

Date Name Dividend *yield Currency
2022 Biogen Inc - - USD
2021 Biogen Inc - - USD
2020 Biogen Inc - - USD
2019 Biogen Inc - - USD
2018 Biogen Inc - - USD
2017 Biogen Inc - - USD
2016 Biogen Inc - - USD
2015 Biogen Inc - - USD
2014 Biogen Inc - - USD
2013 Biogen Inc - - USD
2012 Biogen Inc - - USD
2011 Biogen Inc - - USD
2010 Biogen Inc - - USD
2009 Biogen Inc - - USD
2008 Biogen Inc - - USD
2007 Biogen Inc - - USD
2006 Biogen Inc - - USD
2005 Biogen Inc - - USD
2004 Biogen Inc - - USD
*Yield of the Respective Date

Biogen Inc Calendar

Event Estimate Info Date
Earnings Report 3.389 USD Q1 2023 Earnings Release 04/26/2023
Annual General Meeting - Annual General Meeting 06/14/2023
Earnings Report 3.993 USD Q2 2023 Earnings Release 07/25/2023
Earnings Report - Q3 2023 Earnings Release 10/24/2023
Earnings Report - Q4 2023 Earnings Release 02/01/2024

Biogen Inc Past Events

Event Actual EPS Info Date
Earnings Report 4.050 USD Q4 2022 Earnings Release 02/15/2023
Shareholders' Meeting - - 06/15/2022

Biogen Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
6
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Biogen Shareholder

Owner in %
Freefloat 99.57
PRIMECAP Management Co. 10.87
Vanguard Group, Inc. (Subfiler) 7.88
Vanguard PRIMECAP Fund 6.18
State Street Corp. 4.71
BlackRock Fund Advisors 3.80
Wellington Management Co. LLP 3.75
Vanguard Health Care Fund 3.44
Vanguard Total Stock Market Index Fund 3.07
Vanguard 500 Index Fund 2.32
Geode Capital Management LLC 2.31
BlackRock Institutional Trust Co. NA 2.20
Vanguard Capital Opportunity Fund 1.43
Blackrock Group Ltd. (Subfiler) 1.27
ClearBridge Investments LLC 1.25
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Biogen Management

Name Job
Robert Kilo Account Director
Stelios Papadopoulos Chairman
Robin C. Kramer Chief Accounting Officer & Senior Vice President
Wendell C. Taylor Chief Corporation Counsel & Assistant Secretary
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Ginger Gregory Chief Human Resources Officer & Executive VP
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Maria C. Freire Director
William D. Jones Director
Michael Hencke Executive Director-Investor Relations
Priya Singhal Executive VP, Head-Research & Development
Rachid Izzar Executive Vice President
Nicole Murphy Head-Pharmaceutical Operations & Technology
William A. Hawkins Independent Director
Stephen A. Sherwin Independent Director
Eric K. Rowinsky Independent Director
Richard Charles Mulligan Independent Director
Jesus B. Mantas Independent Director
Caroline D. Dorsa Independent Director
Alexander John Denner Independent Director
Christopher A. Viehbacher President, Chief Executive Officer & Director
Anabella Villalobos SVP-Biotherapeutic & Medicinal Sciences
Susan H. Alexander Secretary, Chief Legal Officer & Executive VP
Rohin Mhatre Senior VP-Product & Technology Development
Michael Dambach Treasurer & Vice President
Jake Elkins Vice President & Head-Acute Neurology Research